NCT04965506View on ClinicalTrials.gov

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

April 28, 2022

Study Completion Date

June 11, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

OTHER

placebo

placebo administered subcutaneously (SC) once a week.

OTHER

Dulaglutide

Dulaglutide administered subcutaneously (SC) once a week.

Trial Locations (1)

100029

China Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter